Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 5Phase NA 2Phase 3 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 291Prostatic Neoplasms 195Neoplasm Metastasis 155Multiple Myeloma 148Colorectal Neoplasms 124Lung Neoplasms 105Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 89Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 81Stomach Neoplasms 76Small Cell Lung Carcinoma 73Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 67Pain 66Carcinoma, Renal Cell 65Uterine Cervical Neoplasms 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

cilgavimab and tixagevimab drug combination 1COVID-19 Vaccines 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × COVID-19 × Clear all
NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Merck Sharp & Dohme LLC

Phase 3 Completed
165 enrolled 13 charts

COVID-19, Papillomavirus Infections

NCT05438498 2023-09-08

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

MediMergent, LLC

Phase 3 Terminated
550 enrolled
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡